BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Five killed in Israeli air strikes on tents near Khan Younis, medics say - 2Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- 3Ukraine to get up to 100 French-made Rafale fighter jets
- 4Russia accidentally destroys its only way of sending astronauts to space
- 5The Best Games Crossroads in History
- Careful Living: Embracing the Current Second
- The Force of Mentorship: Self-improvement through Direction
- Employers and staff feel effect of fuel price rise
- Why the UAE has incurred the wrath of Somalia
- WHO suspends medical evacuations from Gaza following death of contractor in 'security incident'
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- Flu season is underway. What are common symptoms to watch for?
- Brazil Passes Law to Use Seized Bitcoin, Crypto to Fund Public Security Measures
- Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín
